Pharming Group N.V. - ADR | Small-cap | Healthcare
$14.68
-0.81%
| Pharming Group N.V Stock Comparison:
Pharming Group N.V vs VertexPharming Group N.V vs AlnylamPharming Group N.V vs RecursionPharming Group N.V vs AdaptivePharming Group N.V vs Harmony BiosciencesPharming Group N.V vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 93.2M
Gross Profit 84.2M 90.38%
Operating Income 9.0M 9.65%
Net Income 4.6M 4.88%

Balance Sheet Metrics

Total Assets 403.2M
Total Liabilities 187.9M
Shareholders Equity 215.3M
Debt to Equity 0.87

Cash Flow Metrics

Operating Cash Flow 2.1M
Free Cash Flow -56.0K

Revenue & Profitability Trend

Pharming Group N.V Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i297.2M245.3M205.6M204.2M217.9M
Cost of Goods Sold i35.4M25.2M17.6M21.7M24.2M
Gross Profit i261.8M220.1M188.1M182.5M193.7M
Gross Margin % i88.1%89.7%91.5%89.4%88.9%
Operating Expenses
Research & Development i83.1M68.9M52.5M72.3M39.6M
Selling, General & Administrative i99.2M87.5M68.9M49.4M66.7M
Other Operating Expenses i73.7M76.8M49.7M35.3M7.9M
Total Operating Expenses i256.1M233.2M171.0M156.9M114.2M
Operating Income i-3.7M-22.3M9.9M19.5M78.3M
Operating Margin % i-1.2%-9.1%4.8%9.6%35.9%
Non-Operating Items
Interest Income i4.9M3.7M85.0K54.4K734.2K
Interest Expense i8.7M6.0M5.4M6.3M6.1M
Other Non-Operating Income259.0K12.7M10.5M10.5M-27.6M
Pre-tax Income i-8.5M-12.0M15.0M23.7M45.3M
Income Tax i3.3M-1.5M1.3M7.3M6.5M
Effective Tax Rate % i0.0%0.0%8.8%30.7%14.4%
Net Income i-11.8M-10.5M13.7M16.4M38.8M
Net Margin % i-4.0%-4.3%6.7%8.0%17.8%
Key Metrics
EBITDA i14.4M-2.8M22.5M40.3M87.9M
EPS (Basic) i$-0.16$-0.16$0.21$0.24$0.58
EPS (Diluted) i$-0.16$-0.16$0.19$0.22$0.55
Basic Shares Outstanding i6877500065702052651142866422857163626893
Diluted Shares Outstanding i6877500065702052651142866422857163626893

Income Statement Trend

Pharming Group N.V Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i54.9M61.7M207.3M197.1M210.7M
Short-term Investments i112.9M151.7M0--
Accounts Receivable i41.5M35.4M21.0M18.6M24.1M
Inventory i55.7M56.8M42.3M28.0M21.7M
Other Current Assets-----
Total Current Assets i278.4M316.3M277.5M256.1M270.3M
Non-Current Assets
Property, Plant & Equipment i5.4M5.1M4.7M19.5M16.6M
Goodwill i61.0M71.3M75.1M86.1M96.6M
Intangible Assets i61.0M71.3M75.1M86.1M96.6M
Long-term Investments-----
Other Non-Current Assets32.0M31.3M24.1M22.6M33.3M
Total Non-Current Assets i121.5M146.5M148.3M151.8M159.4M
Total Assets i400.0M462.9M425.8M408.0M429.7M
Liabilities
Current Liabilities
Accounts Payable i10.1M16.0M8.8M7.8M13.8M
Short-term Debt i7.2M5.4M5.2M4.4M4.1M
Current Portion of Long-term Debt-----
Other Current Liabilities----25.9M
Total Current Liabilities i73.8M78.0M59.7M48.0M78.9M
Non-Current Liabilities
Long-term Debt i105.1M166.1M161.5M161.7M162.2M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities---169.4K217.7K
Total Non-Current Liabilities i105.1M166.1M161.5M161.9M162.4M
Total Liabilities i178.9M244.1M221.2M209.9M241.3M
Equity
Common Stock i7.8M7.7M7.5M7.6M7.5M
Retained Earnings i-275.5M-265.3M-256.4M-280.5M-303.5M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i221.1M218.8M204.6M198.1M188.3M
Key Metrics
Total Debt i112.3M171.5M166.7M166.1M166.3M
Working Capital i204.6M238.4M217.8M208.1M191.4M

Balance Sheet Composition

Pharming Group N.V Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-8.5M-12.0M15.0M23.7M45.3M
Depreciation & Amortization i16.1M15.9M13.2M20.1M8.5M
Stock-Based Compensation i11.2M9.3M6.4M9.3M6.7M
Working Capital Changes i-7.3M-33.2M-12.4M238.2K-11.2M
Operating Cash Flow i9.6M-15.7M21.6M45.0M81.1M
Investing Activities
Capital Expenditures i-----
Acquisitions i007.3M0-337.8K
Investment Purchases i-284.3M-382.0M0-4.7M0
Investment Sales i316.7M232.8M00-
Investing Cash Flow i32.4M-127.9M7.3M-4.7M-337.8K
Financing Activities
Share Repurchases i-----
Dividends Paid i00000
Debt Issuance i104.5M-00146.7M
Debt Repayment i-138.9M-5.1M-3.3M-3.3M-61.0M
Financing Cash Flow i-34.4M-5.1M-1.0M-24.1M64.5M
Free Cash Flow i-2.6M-18.8M20.5M21.7M70.2M
Net Change in Cash i7.6M-148.7M27.9M16.1M145.3M

Cash Flow Trend

Pharming Group N.V Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 69.31
Forward P/E 293.70
Price to Book 38.60
Price to Sales 2.72

Profitability Ratios

Profit Margin -2.41%
Operating Margin 3.27%
Return on Equity -3.70%
Return on Assets 2.85%

Financial Health

Current Ratio 2.80
Debt to Equity 53.57
Beta 0.59

Per Share Data

EPS (TTM) $-0.14
Book Value per Share $0.35
Revenue per Share $5.04

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
phar953.5M69.3138.60-3.70%-2.41%53.57
Vertex 99.6B28.085.9022.77%31.86%8.89
Alnylam 61.1B-213.71244.95-257.83%-12.96%1,093.31
Recursion 2.0B-2.692.14-86.34%22.65%9.58
Adaptive 1.9B-11.6810.68-57.60%-59.07%121.39
Harmony Biosciences 1.9B10.972.5327.58%23.42%22.43

Financial data is updated regularly. All figures are in the company's reporting currency.